Viking Therapeutics, Inc. (FRA:1VT)

Market Cap	3.04B -15.2%
Revenue (ttm)	n/a
Net Income	-306.30M
EPS	-2.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	412
Open	26.16
Previous Close	26.09
Day's Range	26.16 - 26.16
52-Week Range	16.40 - 39.10
Beta	n/a
RSI	50.60
Earnings Date	Feb 5, 2026

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 53
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1VT

Financial Performance

Financial numbers in USD